Endocyte Inc is a biopharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates or SMDCs and companion imaging diagnose.


Updates from The Motley Fool

Latest updates on Endocyte from Fool.com.
Biotech Bad News Buys

The Biotech Banter crew breaks down recent drops in Seattle Genetics, Pharmacyclics, and Endocyte.

Today's 3 Biotech Blow-Ups

Here's why Endocyte (ECYT), Merrimack Pharmaceuticals (MACK), and Pharmacyclics (PCYC) are fallin...



Stock Performance

View Interactive ECYT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Endocyte.
Current Price: $2.09
Prev Close: $2.11
Open: $2.12
Bid: $2.04
Ask: $2.09
Day's Range: $2.06 - $2.14
52wk Range: $1.98 - $4.33
Volume: 119,610
Avg Vol 189,376
Market Cap: $88M
P/E (ttm): -2.22
EPS (ttm): ($0.95)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Endocyte.
CAPS Rating 4 out of 5
 
93 Outperform
9 Underperform
CAPS All Stars
 
22 Outperform
1 Underperform

How do you think Endocyte will perform against the market?



You pick for Endocyte is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

P. Ron Ellis, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Endocyte.

Endocyte Inc is a biopharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates or SMDCs and companion imaging diagnose.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers